KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Co-Diagnostics (CODX) over the last 9 years, with Q3 2025 value amounting to $11.4 million.

  • Co-Diagnostics' Cash & Equivalents rose 598.57% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 598.57%. This contributed to the annual value of $2.9 million for FY2024, which is 8031.4% down from last year.
  • Co-Diagnostics' Cash & Equivalents amounted to $11.4 million in Q3 2025, which was up 598.57% from $11.1 million recorded in Q2 2025.
  • In the past 5 years, Co-Diagnostics' Cash & Equivalents registered a high of $97.4 million during Q1 2022, and its lowest value of $1.9 million during Q1 2025.
  • Over the past 5 years, Co-Diagnostics' median Cash & Equivalents value was $14.9 million (recorded in 2023), while the average stood at $37.3 million.
  • As far as peak fluctuations go, Co-Diagnostics' Cash & Equivalents soared by 28933.98% in 2021, and later plummeted by 9347.23% in 2023.
  • Co-Diagnostics' Cash & Equivalents (Quarter) stood at $88.6 million in 2021, then plummeted by 74.07% to $23.0 million in 2022, then plummeted by 35.07% to $14.9 million in 2023, then tumbled by 80.31% to $2.9 million in 2024, then soared by 289.71% to $11.4 million in 2025.
  • Its Cash & Equivalents was $11.4 million in Q3 2025, compared to $11.1 million in Q2 2025 and $1.9 million in Q1 2025.